Saverone 2014 revenue was $1.68M for the trailing 12 months ending Dec 31, 2024, with N/A growth year over year. Quarterly revenue for the quarter (Q4 2024) ending on Dec 31, 2024 was N/A, down N/A from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, SVRE annual revenue was $1.7M, with -38.1% growth year-over-year.
SVRE past revenue growth
How has SVRE's revenue growth performed historically?
Saverone 2014 (NASDAQ: SVRE) reported Q4 2024 revenue of N/A up N/A year over year. In the same quarter last year, Saverone 2014's revenue was N/A.
What was Saverone 2014's revenue in 2024?
Saverone 2014's annual revenue for the twelve months ending Dec 31, 2024 was $1.68 million, a 38.13% decrease year over year.
How much does Saverone 2014 make in a day?
Based on Saverone 2014 annual revenue for the past four years, SVRE makes an average of $4,141.10 per day.
What was Saverone 2014's annual revenue growth in the past year?
As of Q2 2025, Saverone 2014's revenue has grown -38.13% year over year. This is 43.74 percentage points lower than the US Scientific & Technical Instruments industry revenue growth rate of 5.61%. Saverone 2014's revenue in the past year totaled $1.68 million.
How much does Saverone 2014 make in a year?
Saverone 2014's revenue by year for the past four years is:
Saverone 2014's revenue for the twelve months ending Dec 31, 2024 was $1.68 million, a 38.13% decrease year over year.
Saverone 2014's annual revenue for Dec 31, 2023 was $2.72 million, a 128% increase from 2022.
Saverone 2014's annual revenue for 2022 was $1.19 million, a 165.11% increase from 2021.
Saverone 2014's annual revenue for 2021 was $450.00 thousand, a 42.41% increase from 2020.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.